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The impairment of cerebral glucose utilization is an early and predictive biomarker of
Alzheimer’s disease (AD) that is likely to contribute to memory and cognition disorders
during the progression of the pathology. Yet, the cellular and molecular mechanisms
underlying these metabolic alterations remain poorly understood. Here we studied
the glucose metabolism of supragranular pyramidal cells at an early presymptomatic
developmental stage in non-transgenic (non-Tg) and 3xTg-AD mice, a mouse model
of AD replicating numerous hallmarks of the disease. We performed both intracellular
glucose imaging with a genetically encoded fluorescence resonance energy transfer
(FRET)-based glucose biosensor and transcriptomic profiling of key molecular elements
of glucose metabolism with single-cell multiplex RT-PCR (scRT-mPCR). We found that
juvenile pyramidal cells exhibit active glycolysis and pentose phosphate pathway at
rest that are respectively enhanced and impaired in 3xTg-AD mice without alteration
of neuronal glucose uptake or transcriptional modification. Given the importance of
glucose metabolism for neuronal survival, these early alterations could initiate or at least
contribute to the later neuronal dysfunction of pyramidal cells in AD.
Keywords: glucose uptake, glycolysis, pentose phosphate pathway, FRET imaging, single-cell RT-PCR
INTRODUCTION
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by progressive cognitive
impairment and memory loss. The underlying neuropathology includes brain deposition of
amyloid plaques formed by misfolded amyloid-β (Aβ), neurofibrillary tangles and neuronal loss
(Braak and Braak, 1991; Hardy and Selkoe, 2002). The visualization by 18-fluoro-2-deoxy-D-
glucose positron emission tomography of a decreased cerebral glucose utilization occurring in
specific brain regions is one of the earliest functional signs of AD (Small et al., 2000; Dubois et al.,
2016). It aggravates with the disease progression and even predicts the neuropathological diagnosis
of AD (Mosconi, 2005; Mosconi et al., 2010).
The most vulnerable brain regions to Aβ deposition corresponds to areas where glucose is
physiologically used beside its role as a substrate for oxidative phosphorylation in spite of oxygen
availability (Vaishnavi et al., 2010; Vlassenko et al., 2010). This non-oxidative glucose utilization is
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referred to as “aerobic glycolysis” and includes the glycolysis
itself, the pentose phosphate shunt and the glycogen synthesis.
Under physiological conditions, these glucose metabolic
pathways are highly compartmentalized between neurons and
glial cells, glycolysis, and glycogen synthesis occurring mainly
in astrocytes (Allaman et al., 2011; Fernandez-Fernandez et al.,
2012).
Deregulation of the neuronal metabolic program can be
deleterious since hyperactive glycolysis and glycogen synthesis
in neurons are pro-apoptotic (Vilchez et al., 2007; Herrero-
Mendez et al., 2009). In addition, the pentose phosphate
pathway promotes long-term neuronal survival (Vaughn and
Deshmukh, 2008) and the non-oxidative use of glucose in
the hexosamine biosynthetic pathway protects tau protein
from hyperphosphorylation and restricts neurofibrillary tangles
formation (Liu et al., 2009). Hence, an early alteration of neuronal
glucose metabolism is likely to initiate or at least contribute
to later neural dysfunctions and neurodegenerative processes
characteristic of AD.
Although in vivo studies are considered as the reference
standard to measure glucose metabolism (Sokoloff et al., 1977;
Fox and Raichle, 1986; Fox et al., 1988), they generally lack
the required resolution to investigate cellular processes and
offer limited pharmacological investigations (Sotelo-Hitschfeld
et al., 2015; Diaz-Garcia et al., 2017). Conversely, in vitro
models provide an excellent spatial and temporal resolution but
are largely based on culture systems derived from embryonic
or neonate animals (Bittner C.X. et al., 2010; Surin et al.,
2012; Tantama et al., 2013; Lerchundi et al., 2015). Given
that brain metabolism undergoes substantial changes during
embryonic and postnatal development (Bilger and Nehlig, 1992;
Nehlig and Pereira de Vasconcelos, 1993; Nehlig, 1999; Surin
et al., 2012) these in vitro models may not be appropriate
to study age-related neurological disorders. The acute slice
(ex vivo) models provide an intermediate approach preserving
the cytoarchitecture of brain tissues also allowing cell-type
specific investigations (Kasischke et al., 2004; Choi et al., 2012;
Sotelo-Hitschfeld et al., 2015; Diaz-Garcia et al., 2017) but
require careful design of experimental conditions (Iadecola and
Nedergaard, 2007).
3xTg-AD mice is a model that replicates the neuropathological
hallmarks of AD (Oddo et al., 2003; Carroll et al., 2010). In
these mice, glucose metabolic impairments are already observed
during embryogenesis (Yao et al., 2009) and progress during
aging, thus preceding the apparition of Aβ deposition and
tau hyperphosphorylation (Nicholson et al., 2010; Ding et al.,
2013; Sancheti et al., 2014a,b; Sanguinetti et al., 2018). Since
cerebral metabolism switches from ketone bodies to glucose
utilization during the first postnatal weeks (Bilger and Nehlig,
1992; Nehlig and Pereira de Vasconcelos, 1993; Nehlig, 1999)
this developmental stage might represent a critical step in the
emergence of glucose metabolism alterations. Layer II and III
pyramidal neurons already contribute to glucose supply via
neurovascular interactions during this period (Cauli and Hamel,
2010; Lecrux et al., 2011; Lacroix et al., 2015) and have been
reported to degenerate before Aβ deposition in 3xTg-AD mice
(Bittner T. et al., 2010), suggesting an early involvement in the
pathogenesis of AD. We therefore underwent our investigations
at a presymptomatic juvenile stage corresponding to the
developmental metabolic switch by comparing the metabolic
program of supragranular pyramidal neurons of non-Tg and
3xTg-AD mice.
We used a genetically encoded fluorescence resonance energy
transfer (FRET)-based glucose biosensor (Deuschle et al., 2005;
Takanaga et al., 2008; Bittner C.X. et al., 2010) to investigate the
uptake and fate of glucose at a cellular resolution and single-
cell multiplex RT-PCR (scRT-mPCR) to determine the expression
profiles of key elements of glucose metabolism of pyramidal
cells. We report that both glycolysis and pentose phosphate
pathways are active in juvenile pyramidal cells at rest. These
fluxes are respectively enhanced and reduced in 3xTg-AD mice,
without alteration of neuronal glucose uptake or transcriptional
modification.
MATERIALS AND METHODS
Animals
Homozygous 3xTg-AD (MMRRC #034830) generated and
maintained on a mixed J29/C57BL6 background and wild type
non-transgenic mice of the same background as well as C57BL6
background (11–19 postnatal days) of both genders were used
for glucose imaging and patch-clamp recordings in acute slices.
3xTg-AD mice express the mutated gene PS1M146V (knock-in)
and the mutated human genes APPSwe and tauP301L in the same
locus, both under the control of the mouse Thy1.2 regulatory
element and were routinely genotyped by PCR (Oddo et al.,
2003). All animals were housed in a temperature-controlled (21–
25◦C) room under 12 h light:12 h dark conditions and were given
food and water ad libitum. A maximum of five mice were housed
per cage and single animal housing was avoided. All experimental
procedures using animals were performed in strict accordance
with French regulations (Code Rural R214/87 to R214/130)
R214/126 and conformed to the ethical guidelines of both the
European Economic Community (86/609/EEC) and the French
National Charter on the ethics of animal experimentation. All
protocols were approved by the Charles Darwin ethics committee
and submitted to the French Ministry of Education and Research
(Approval 2015 061011367540 APAFIS#573-2015061011367547
v1). The IBPS animal facility is accredited by the French
authorities (A75-05-24).
Subcloning and Viral Production
The glucose sensor FLII12Pglu-700µδ6 (Takanaga et al., 2008)
was used in this study. The coding sequence of the sensor was
subcloned into the viral vector pSinRep5 (Invitrogen). Sindbis
virus were produced as previously described (Hepp et al., 2007;
Hu et al., 2011). Recombinant pSinRep5 and helper plasmid
pDH26S were transcribed in vitro into capped RNA using the
Megascript SP6 kit (Ambion). Baby hamster kidney-21 (ATGC
#CCL-10) cells were electroporated with sensor-containing RNA
and helper RNA (2× 107 cells, 950 µF, 230 V) and incubated for
24 h at 37◦C in 5% CO2 in Dulbecco’s modified Eagle Medium
supplemented with 5% fetal calf serum before collecting cell
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supernatant containing the viruses. The virus titer (108 infectious
particles/ml) was determined after counting fluorescent baby
hamster kidney cells infected using serial dilution of the stock
virus.
Slice Preparation
Mice were deeply anesthetized with isoflurane. After decapitation
brains were quickly removed and placed into cold (∼4◦C)
oxygenated artificial cerebrospinal fluid (aCSF) containing (in
mM): 126 NaCl, 2.5 KCl, 1.25 NaH2PO4, 2 CaCl2, 1 MgCl2, 26
NaHCO3, 10 glucose, 15 sucrose, and 1 kynurenic acid (Sigma).
Coronal slices (300 µm thick) containing the barrel cortex were
cut with a vibratome (VT1000S; Leica) and allowed to recover at
room temperature for at least 1 h in aCSF saturated with O2/CO2
(95%/5%) as previously described (Karagiannis et al., 2009).
Brain Slice Viral Infection
Brain slices were placed onto a millicell-CM membrane
(Millipore) with culture medium (50% minimum essential
medium, 50% Hank’s balanced salt sodium, 6.5 g/l glucose
(∼36 mM), and 100 U/ml penicillin/100 µg/ml streptomycin;
Invitrogen) as previously described (Drobac et al., 2010; Hu et al.,
2011). Infection was performed by adding ∼5 × 105 particles
per slice. Slices were incubated overnight at 35◦C in 5% CO2.
The next morning, brain slices were equilibrated for 1 h in
aCSF containing (in mM): 126 NaCl, 2.5 KCl, 1.25 NaH2PO4,
2 CaCl2, 1 MgCl2, 26 NaHCO3, 2.5 glucose, and 22.5 sucrose
to reduce glucose concentration to a physiological level (Silver
and Erecinska, 1994). Slices were then placed into the recording
chamber, heated at ∼30◦C and continuously perfused at 1–
2 ml/min.
Double-Immunofluorescence Labeling
Following viral transduction, slices were fixed overnight at
4◦C in 0.1 M phosphate-buffer containing 4% formaldehyde.
Then, slices were rinsed with phosphate-buffer saline (PBS),
permeabilized with PBS/gelatin 0.2%/Triton 0.25%, and
incubated overnight at 4◦C with rabbit anti-Satb2 (1:1000,
ab34735, Abcam; Lee et al., 2010) and chicken anti-GFP (1:1000,
GFP-1020, Aves Labs; Tricoire et al., 2010). After washing in
PBS, the respective immunoreactions were visualized with the
following secondary antibodies: goat-anti-rabbit AlexaFluor
555 (1:1000, A-21430, Thermo Fisher Scientific) and goat-anti
chicken AlexaFluor 488 (1:1000, A-11039, Thermo Fisher
Scientific) incubated 1 h at room temperature. Sections were
mounted with fluoromount-G (Southern Biotech) on slides
for visualization. Images of immunostained material were
acquired using a Leica TCS SP5 AOBS inverted confocal
microscope with a 40× objective (40× HCX P APO CS NA
1.25–0.75/Oil) and LAS AF software (Leica Microsystems). Cell
counting was performed using Image Pro Analyzer 7.0.0.951
(MediaCybernetics).
FRET Imaging
Recordings were made from visually identified pyramidal cells
in layer II and III of the mouse somatosensory cortex. Wide-
field fluorescent images were obtained using a double port
upright microscope (BX51WI, WI-DPMC Olympus) with a
40x objective (LUMPlan FL N 40×/0.80 W) and a digital
camera (CoolSnap HQ2, Roper Scientific or Orca Flash 4.0,
Hamamatsu) attached on the front port of the microscope. The
glucose sensor FLII12Pglu-700µδ6 was excited at 400 nm with
a light emitting device (LED; CoolLED, Precise Excite) using
Imaging Workbench 6.0.25 software (INDEC BioSystems) and
excitation (HC 438/24, Semrock) and dichroic filters (HC BS 458,
Semrock). Double fluorescence images were collected every 15 s
by alternating the fluorescence emission filters for the CFP (HC
483/32 Semrock) and the YFP (HC 542/27, Semrock) using a filter
wheel (Lambda 10B, Sutter Instruments). In parallel, infrared
transmitted light images of slices were continuously monitored
on the back-port of the microscope using an infrared collimated
LED as a light source (780 nm, Thorlabs), Dodt gradient contrast
optics (DGC; Luigs and Neumann; Dodt and Zieglgansberger,
1998), a customized beam splitter (725 DCSPXR, Semrock) and
an analogic CCD camera (XC ST-70 CE, Sony). The focal plane
was maintained constant on-line using infrared DGC images
of cells as anatomical landmarks (Lacroix et al., 2015). To
compensate for potential x–y drifts all images were realigned
off-line using the “StackReg” plug-in (Thevenaz et al., 1998)
of ImageJ 1.48 software. Fluorescence ratios were calculated
by dividing the registered YFP images by the registered CFP
images using FIJI1. On average 8.0 ± 0.3 transduced neurons
were visualized in the field of view of the CoolSnap HQ2 with
no statistical difference between 3xTg-AD and non-Tg mice
(U(29,30) = 390, p = 0.5027). To determine regions of interests
(ROIs) corresponding to the cytosolic part of the soma, nuclei
were manually delineated and excluded from somatic ROIs. The
mean ratio was measured at each time point using the same
ROIs. The experiments lasted more than 30 min, leading to
a small drift in the ratio baseline (Figure 2B). The drift was
corrected by a linear curve fitting (John et al., 2008) using
Clampfit 10.4 software (MDS). Variations of fluorescence ratio
were expressed as the ratio (R–R0)/R0, where R corresponds
to the fluorescence ratio in the ROI at a given time point,
and R0 corresponds to the mean fluorescence ratio in the
same ROI during the 10 min control baseline prior to changes
in extracellular glucose concentration or application of drugs.
Relative ratio traces were smoothed with a sliding five-point
median filter to eliminate sharp artifacts resulting from transient
loss of focus.
Whole-Cell Recordings in Acute Slices
Patch pipettes (4–6 M) pulled from borosilicate glass were
filled with 8 µl of RNAse free internal solution containing in
(mM): 144 K-gluconate, 3 MgCl2, 0.5 EGTA, 10 HEPES, pH
7.2 (285/295 mOsm). Whole-cell recordings were performed at
27.0 ± 0.5◦C using a patch-clamp amplifier (Axopatch 200B,
MDS). Data were filtered at 5–10 kHz and digitized at 50 kHz
using an acquisition board (Digidata 1440, MDS) attached to
a personal computer running pCLAMP 10.2 software package
(MDS). Membrane potential values were corrected for liquid
junction potential (−15.6 mV). Resting membrane potential
1http://fiji.sc/Fiji
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of neurons was measured just after passing in whole-cell
configuration. Only neurons with a resting membrane potential
more negative than −60 mV were analyzed further. A total
of 32 electrophysiological properties chosen to describe the
electrophysiological diversity of cortical neurons (Ascoli et al.,
2008) were determined as previously described (Karagiannis
et al., 2009).
Cytoplasm Harvesting and scRT-PCR
At the end of the whole-cell recording, lasting <15 min, the
cytoplasmic content was aspirated in the recording pipette. The
pipette’s content was expelled into a test tube and RT was
performed in a final volume of 10 µl, as described previously
(Lambolez et al., 1992). The scRT-PCR protocol was designed
to probe simultaneously the expression of neuronal markers
and key molecular elements of glucose metabolism. Two-steps
amplification was performed essentially as described (Cauli
et al., 1997; Devienne et al., 2018). Briefly, cDNAs present in
the 10 µl reverse transcription reaction were first amplified
simultaneously using all external primer pairs listed in Table 1.
Taq polymerase (2.5 U; Qiagen) and 20 pmol of each primer
were added to the buffer supplied by the manufacturer (final
volume, 100 µl), and 20 cycles (94◦C, 30 s; 60◦C, 30 s; and
72◦C, 35 s) of PCR were run. Second rounds of PCR were
performed using 1 µl of the first PCR product as a template. In
this second round, each cDNA was amplified individually using
its specific nested primer pair (Table 1) by performing 35 PCR
cycles (as described above). A ten µl of each individual PCR
product were run on a 2% agarose gel stained with ethidium
bromide using 8X174 digested by HaeIII as a molecular weight
marker.
Drugs
Changes in extracellular glucose concentration were
compensated by changes in sucrose concentration to maintain
the osmolarity of the aCSF constant as previously described (Miki
et al., 2001). Iodoacetic acid (IAA) and 6-aminonicotinamide
(6-AN) were purchased from Sigma-Aldrich.
Statistical Analyses
Statistical analyses were performed with Statistica 6 (Statsoft).
All values are expressed as mean ± SEM. Statistical significance
of FRET ratio changes and electrophysiological properties of
pyramidal cells of 3xTg-AD and non-Tg mice was determined
using the Mann–Withney U test. Comparison of the occurrence
of the genes expressed by pyramidal cells of the two mice lines was
determined using Fisher’s exact test. Statistical significance on all
figures uses the following convention: ∗p < 0.05, ∗∗p < 0.01, and
∗∗∗p < 0.001.
TABLE 1 | PCR primers.
Genes Accession # First PCR primers Size (bp) Second PCR nested primers Size (bp)
vGluT1 Sense, −113: GGCTCCTTTTTCTGGGGCTAC 259 Sense, −54: ATTCGCAGCCAACAGGGTCT 153
NM_182993 Antisense, 126: CCAGCCGACTCCGTTCTAAG Antisense, 79: TGGCAAGCAGGGTATGTGAC
GAD65 Sense, 99: CCAAAAGTTCACGGGCGG 375 Sense, 219: CACCTGCGACCAAAAACCCT 248
NM_008078 Antisense, 454: TCCTCCAGATTTTGCGGTTG Antisense, 447: GATTTTGCGGTTGGTCTGCC
GAD67 Sense, 529: TACGGGGTTCGCACAGGTC 598 Sense, 801: CCCAGAAGTGAAGACAAAAGGC 255
NM_008077 Antisense, 1,109: CCCAGGCAGCATCCACAT Antisense, 1,034: AATGCTCCGTAAACAGTCGTGC
GluT1 Sense, 5: ATCCCAGCAGCAAGAAGGTGA 333 Sense, 88: ACTGGTGTCATCAACGCCCC 164
NM_011400 Antisense, 317: AGAAGCCCATAAGCACAGCAG Antisense, 230: CCGACAGAGAAGGAACCAATCA
GluT3 Sense, 1: ATGGGGACAACGAAGGTGAC 358 Sense, 23: CATCTCTGGTGTTCGCCGT 310
NM_011401 Antisense, 336: GCATTTCAACAGACTCCGCTATC Antisense, 314: GCGAATCCCATAAGGCAGC
HK1 Sense, 879: CGAGAAGATGGTGAGCGGC 472 Sense, 986: TCACGAGGGGCAAGTTCACC 330
NM_001146100 Antisense, 1,333: GCCACTGCCACTCTCCGA Antisense, 1,298: CCGAGTCAGGCACCAGGC
Pfkfb3 Sense, 211: GTGGGAGAGTATCGGCGTGA 494 Sense, 255: CAACTTCTTCCGCCCTGACA 365
NM_001177752 Antisense, 685: ATTCGGCTCTGGATGTGGTC Antisense, 596: CACATTTATCAGGGTCAAGAGGCT
PFK1m Sense, 49: GCCATCGCCGTGTTGACC 247 Sense, 106: GCTGTGGTCCGAGTTGGTATCT 160
NM_001163487 Antisense, 276: GTCGTCCTTCTCGCTCTCGG Antisense, 246: ATCGGGCACTTCCAATCACT
PFK1l Sense, 180: AGGAGGCGAGAACATCAAGC 408 Sense, 304: GCCTACAATCTGCTCCAACACG 169
NM_008826 Antisense, 568: GCAGTGGTAGTGATGGCGTC Antisense, 451: TGGTCAAGTGTGCGTAGTTCTG
PFK1p Sense, 409: CGAAAGGAGTGGAGCGGA 306 Sense, 438: GCTGGCTCGGAATGGTGAT 219
NM_019703 Antisense, 696: AAGGAACACCCAGTCGGCA Antisense, 637: TGTCTCCCCATCACCTCCAG
G6PDx Sense, 206: GCTATGCCCGCTCACGAC 303 Sense, 491: CCACGATGATGCGGTTCC 143
NM_008062 Antisense, 232: GACGACATCCGAAAGCAGAGTG Antisense, 353: ATGTGGCTGTTGAGGTGCTTAT
Gys1 Sense, 3: GCCTCTCAGCCGCAGTCT 313 Sense, 66: CGACCCCGAGAACGCAGT 157
NM_030678 Antisense, 294: ACGCCCAAAATACACCTTACAA Antisense, 205: CCTCACACCCTGCTCCGT
PygB Sense, 108: GCATTTCACGCTGGTCAAGG 292 Sense, 156: CTTCTTCGCTCTGGCACACA 110
NM_153781 Antisense, 380: CCCAAGACCAGCATCCTCCT Antisense, 244: CCAGGGAAAGGTAATAGATGCG
Position 1, first base of the start codon.
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RESULTS
Glucose Uptake
We used a recombinant Sindbis virus (see Materials and
Methods) to express the FRET glucose sensor FLII12Pglu-
700µδ6 (Takanaga et al., 2008) in neurons of neocortical slices.
Expression of the biosensor was preferentially observed in
pyramidal shaped cells of layers II and III (Figures 1, 2A),
consistent with previous reports (Drobac et al., 2010; Hu et al.,
2011). The sensor was observed both in somata and in proximal
dendrites, but virtually absent from nuclei (Figures 1, 2A). The
pyramidal identity of transduced cells was next examined by
double immunofluorescence for GFP and Satb2, a pyramidal
cells transcription factor (Britanova et al., 2008; Lee et al., 2010;
Lacroix et al., 2015). A large majority of transduced cells displayed
a nucleus positive for Satb2 (75.1± 3.1%, n = 415 GFP-expressing
cells from three different mice) confirming the pyramidal tropism
of the Sindbis virus (Chen et al., 2000; Lendvai et al., 2000; Furuta
et al., 2001; Drobac et al., 2010). Optical recordings were then
performed in layer II and III by measuring the YFP/CFP emission
ratio of the biosensor in the cytosol.
The resting intracellular glucose concentration is determined
by glucose transport (uptake and efflux) and metabolism
(Bittner C.X. et al., 2010; Hou et al., 2011). We first evaluated
the capability of supragranular neuron to take-up glucose by
monitoring dynamic changes in intracellular glucose during
an increase in extracellular glucose concentration (John et al.,
2008; Takanaga et al., 2008; Hou et al., 2011). Increasing
extracellular glucose from 2.5 mM, a physiologically relevant
glucose concentration (Silver and Erecinska, 1994), to 10 mM,
a glucose concentration nearly saturating the sensor (Takanaga
et al., 2008) and classically used in brain slices experiments,
lead to a slowly developing increase in fluorescence emission
FIGURE 1 | Expression of the FRET glucose sensor in neocortical slices.
Representative single plane confocal image of a slice expressing the
FLII12Pglu-700 µδ6 biosensor following sindbis viral transduction. Cells
expressing the FRET glucose sensor are identified by their GFP fluorescence
(green). Pyramidal cells are immunolabeled for the Satb2 transcription factor
(red). Dashed line represents layer I and II border. Note that most layer II and III
transduced cells are stab2 positive.
ratio (Figures 2B,C). This confirms that pyramidal neurons from
juvenile mice of both genotypes have the capability to take up
glucose (Diaz-Garcia et al., 2017).
During application of 10 mM glucose the relative increase
in fluorescence ratio was 3.8 ± 0.3% in non-Tg neurons vs.
3.2 ± 0.3% in 3xTg-AD neurons after 10 min [U(74,57) = 1,787,
p = 0.1359], 5.9 ± 0.4% vs. 5.6 ± 0.6% [U(74,57) = 1,844,
p = 0.2203] after 20 min, 7.4 ± 0.5% vs. 6.9 ± 0.7%
[U(74,57) = 1,822, p = 0.1841] after 30 min, 8.8 ± 0.6%
vs. 8.4 ± 0.9% [U(74,57) = 1,843, p = 0.2185] after 40 min
and 10.2 ± 0.7% vs. 9.4 ± 1.1% after [U(74,57) = 1,785,
p = 0.1335] after 50 min. These results revealed that the
glucose accumulations were very similar between pyramidal
cells of juvenile non-Tg and 3xTg-AD mice (Figure 2C). Since
in slices we cannot estimate the resting intracellular glucose
concentration, we next thought to determine whether the
elimination rate of glucose was similar. To do so, we reduced
extracellular glucose concentration close to 0 (Bittner C.X. et al.,
2010).
Glucose Metabolic Activity
Decreasing extracellular glucose from 2.5 to 0.2 mM led to a
marked drop in relative fluorescence ratio (Figure 3A). This
indicates that pyramidal cells metabolize glucose under resting
condition as recently reported (Diaz-Garcia et al., 2017). The
slopes of intracellular glucose decrease, measured between 2 and
7 min after glucose restriction, were not statistically different
between non-Tg and 3xTg-AD pyramidal cells [−2.0 ± 0.0%
min−1 vs. −2.2 ± 0.1% min−1, U(65,88) = 2,666, p = 0.4740].
This indicates that the elimination rates of glucose, which depend
on both efflux and metabolism, were similar. Taken together,
the similar accumulation and elimination rates we observed
(Figures 2, 3) revealed that the capabilities of glucose transport
are comparable between non-Tg and 3xTg-AD pyramidal cells.
Nonetheless, scrutinization of the dynamics of intracellular
glucose revealed subtle differences between the metabolic
activity of pyramidal cells of juvenile non-Tg and 3xTg-
AD mice (Figure 3A). After 5 min of extracellular glucose
restriction, the drop was stronger in non-Tg than in 3xTg-
AD mice [−6.8 ± 0.4% vs. −5.5 ± 0.3%, U(65,88) = 2,087,
p = 0.0043] indicating a higher metabolic activity in non-
Tg mice at an early stage of glucose restriction (Figure 3).
However it did not differ after 10 min of glucose restriction
[−15.2 ± 0.3% vs. −16.1 ± 0.4%, U(65,88) = 2,444, p = 0.1247,
Figure 3B]. Interestingly, longer glucose restrictions disclosed a
higher elimination rate of glucose in 3xTg-AD pyramidal cells
(Figure 3), which was evident after 15 min [−19.0 ± 0.3% vs.
−20.3 ± 0.4%, U(65,88) = 2,029, p = 0.0022] and persisted after
20 min [−20.8 ± 0.4% vs. −21.9 ± 0.5%, U(65,88) = 2,237,
p = 0.0215, Figure 3B]. The lower and higher glucose elimination
rates, respectively observed at early and late stages of glucose
depletion in 3xTg-AD pyramidal cells, may suggest that at
least two glucose pathways with different kinetics are altered.
The similar elimination rates we observed indicate that these
alterations roughly counterbalance each other.
To evaluate the relative contribution of different glucose
pathways to the metabolic activity of pyramidal cells, we
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FIGURE 2 | Glucose uptake in layer II and III pyramidal cells. (A) The gray scale image shows the YFP fluorescence. Pseudocolor images show the YFP/CFP ratio
value [coded by pixel hue, see scale bar in (a)] and the fluorescence intensity (coded by pixel intensity) at different time points before (a) and after (b,c) superfusion of
10 mM glucose. (B) Traces show average YFP/CFP ratio measure at the cytosolic part of the soma of individual pyramidal cells delineated in (A). (a–c) indicate time
points corresponding to the pseudocolor images shown in (A). (C) Mean relative YFP/CFP ratio changes in pyramidal cells of non-Tg (black trace) and 3xTg-AD mice
(red trace) induced by superfusion of 10 mM glucose. Traces show mean (solid lines) ± standard errors of the mean (color shades). Note the slowly developing
increase in mean relative ratio during 10 mM glucose superfusion and the similar temporal profiles between non-Tg and 3xTg-AD mice.
monitored glucose accumulation induced by different metabolic
inhibitors. We first inhibited glycolysis using IAA, a widely used
glyceraldehyde-3-phosphate dehydrogenase (G3PDH) inhibitor
that does not interfere with the FRET glucose sensors (John
et al., 2008; Bittner C.X. et al., 2010). We used 200 µM
IAA, a concentration that efficiently inhibits glycolysis in
brain slices (Yang et al., 1999; Gordon et al., 2008) with
modest impact on the pentose phosphate pathway or lactate
dehydrogenase activity (Sabri and Ochs, 1971; Schmidt and
Dringen, 2009). Bath application of IAA induced a delayed
increase in relative fluorescence ratio in non-Tg pyramidal cells
(Figure 4A1), indicative of glucose accumulation and consistent
with glycolytic activity in cortical neurons under resting
condition (Bittner C.X. et al., 2010; Diaz-Garcia et al., 2017).
Surprisingly, in pyramidal cells of 3xTg-AD mice IAA led
to a biphasic response consisting in a transient decrease in
intracellular glucose followed by a latter increase (Figure 4A1).
The transient decrease, absent in pyramidal cells of non-
Tg mice, was observable after 10 min of IAA application
[0.7 ± 0.2% vs. −0.7 ± 0.6%, U(81,34) = 569, p = 2.480×10−7,
Figure 4A2] and lasted for about 10 min. At that time
of glycolysis inhibition, the intracellular glucose dynamics of
non-Tg and 3xTg-AD pyramidal cells crossed (Figure 4A1)
and did not differ significantly [0.2 ± 0.5% vs. 1.8 ± 1.4%,
U(81,34) = 1,341, p = 0.8286, Figure 4A2]. This transient
decrease in glucose level observed under glycolysis inhibition
suggests that another glucose-consuming metabolic pathway
was stimulated or at least disclosed. A longer exposure to
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FIGURE 3 | Metabolic activity of layer II and III pyramidal cells. (A) Mean
relative YFP/CFP ratio changes in pyramidal cells of non-Tg (black trace) and
3xTg-AD mice (red trace) induced by glucose (Glc) restriction (0.2 mM). Traces
show mean (solid lines) ± standard errors of the mean (color shades). Note
the slowly developing decrease in mean relative ratio during 0.2 mM Glucose
superfusion. Note also the difference in the temporal profiles between non-Tg
and 3xTg-AD mice. (B) Histograms show the metabolic activity (decrease in
relative YFP/CFP ratio) at different time of glucose restriction. After 5 min of
glucose restriction pyramidal cells of non-Tg mice exhibit a higher metabolic
activity than those of 3xTg-AD mice. In contrast, during longer glucose
restriction pyramidal cells of 3xTg-AD mice display a higher metabolic activity.
n.s. not statistically significant.
IAA revealed a higher intracellular glucose increase in 3xTg-
AD neurons [7.0 ± 0.8% vs. 14.4 ± 1.7%, U(81,34) = 636,
p = 2.715×10−6 at 30 min]. These observations suggest that the
glycolysis rate is higher in 3xTg-AD than in non-Tg pyramidal
cells.
We next evaluated the importance of the pentose phosphate
shunt in the metabolism of pyramidal cells and thought
to determine whether it is altered in 3xTg-AD pyramidal
cells. Applying 6-AN induced a slowly developing increase in
intracellular glucose concentration in non-Tg pyramidal cells
(Figure 4B1). After 30 min the amplitude of this increase reached
a level comparable to the one observed under glycolysis inhibition
(Figures 4A1, B1), indicating that both pathways contribute to
the resting glucose metabolism of pyramidal cells.
In contrast, in 3xTg-AD neurons 6-AN induced a slight and
transient decrease in intracellular glucose observable after 10 min
[1.7± 0.3% vs.−0.4± 0.3%, U(78,58) = 1,120, p = 2.393×10−7]
followed by a very mild increase at 20 min [2.9 ± 0.5% vs.
0.3 ± 0.4%, U(78,58) = 1,365, p = 6.195×10−5] and 30 min
of exposure [4.7 ± 0.8% vs. 0.9 ± 0.6%, U(78,58) = 1,389,
p = 9.861×10−5, Figure 4B2], respectively. These results reveal
that the pentose phosphate pathway is dramatically hampered in
3xTg-AD neurons.
In order to investigate further the metabolic pathway
disinhibited in 3xTg-AD neurons during glycolysis inhibition, we
simultaneously applied IAA and 6-AN to inhibit both glycolysis
and the pentose phosphate pathway. Such a combined inhibition
induced a biphasic response in both non-Tg and 3xTg-AD
pyramidal cells consisting in a small and transient decrease in
intracellular glucose followed by a later increase (Figure 4C1).
However, the initial dip in intracellular glucose was much
stronger and longer lasting in 3xTg-AD neurons (Figure 4C1).
Indeed, it was comparable after 10 min of combined inhibition
[−0.3 ± 0.2% vs. −0.6 ± 0.3%, U(76,43) = 1,479, p = 0.3943]
and was particularly marked after 20 min [−1.3 ± 0.4% vs.
−3.3 ± 0.7%, U(76,43) = 1,228, p = 0.0245, Figure 4C2]. Since
this transient glucose consumption in 3xTg-AD neurons was
observed under both glycolysis (Figure 4A1) and combined
inhibition (Figure 4C1) and barely during inhibition of the
pentose phosphate pathway alone (Figure 4B1), it indicates that
glycolysis inhibition is required to disclose the initial dip. It also
suggests that the pentose phosphate pathway does not chiefly
underlay this transient glucose consumption. A longer combined
inhibition resulted in an intracellular glucose increase that was
higher in non-Tg than in 3xTg-AD pyramidal cells [10.2 ± 0.7%
vs. 7.1 ± 1.0%, U(76,43) = 1,267, p = 0.0423, Figures 4C1, C2].
These observations suggest that the lower pentose phosphate
activity observed in 3xTg-AD (Figure 4A) neurons is partially
compensated by a higher glycolytic activity (Figures 4B,C).
Molecular Characterization of Layer II
and III Pyramidal Cells
To determine the main genes of glucose metabolism underlying
the metabolic program of pyramidal cells and to evaluate whether
transcriptomic modifications could mediate the alterations
observed in 3xTg-AD mice, we analyzed the expression profiles
of these genes in non-Tg and 3xTg-AD pyramidal cells by
single cell RT-multiplex PCR (scRT-mPCR). The protocol was
designed to probe the expression of vGluT1 and GAD65 and
67, taken as glutamatergic and GABAergic markers, respectively.
The key genes of glucose metabolism included two glucose
transporters GluT1 and GluT3, the hexokinase isoform HK1, the
main brain phosphofructokinase-2 isoform; Pfkfb3, the muscle,
liver and platelet isoforms of phosphofructokinase-1 (PFK1m,
l and p), the rate limiting enzyme of the pentose phosphate
pathway (glucose-6-phosphate dehydrogenase, G6PDx), as well
as glycogen synthase and phosphorylase isoforms Gys1 and PygB.
The reliability of the scRT-mPCR was tested on 1 ng of total
RNA purified from mouse whole brain. As expected, all PCR
generated fragments had the sizes predicted by their mRNA
sequences (Figure 5 and Table 1) confirming the sensitivity of
the amplification procedure (Cauli et al., 1997).
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FIGURE 4 | Glucose metabolic pathways in layer II and III pyramidal cells. Left panels show the mean relative YFP/CFP ratio changes in pyramidal cells of non-Tg
(black traces) and 3xTg-AD mice (red traces) induced by glycolysis inhibition with IAA (A1), pentose phosphate pathway inhibition with 6-AN (B1), and combined
inhibition with both IAA and 6-AN (C1). Traces show mean (solid lines) ± standard errors of the mean (color shades). Histograms show the metabolic activity
(decrease in relative YFP/CFP ratio) at different time of glycolysis inhibition (A2), pentose phosphate pathway inhibition (B2), and combined inhibition (C2). n.s. not
statistically significant. (A1) Note the delayed increase in mean relative ratio in non-Tg pyramidal cells during IAA application. Note also the early decrease followed
by a late increase in pyramidal cells of 3xTg-AD mice. (A2) After 10 min of IAA application pyramidal cells of 3xTg-AD mice develop a transient increase in metabolic
activity. Longer application reveals a larger impact of glycolysis inhibition in pyramidal cells of 3xTg-AD mice than in pyramidal cells of non-Tg mice. (B1) Note the
very low increase in mean relative ratio during 6-AN application in pyramidal cells of 3xTg-AD mice. (B2) The mean increase in relative ratio is higher in pyramidal cells
of non-Tg mice at 10, 20, and 30 min of 6-AN superfusion. (C1) Note the transient decrease in mean relative ratio during combined IAA and 6-AN application more
pronounced in pyramidal cells of 3xTg-AD mice than in non-Tg neurons. (C2) After 20 min of combined inhibition pyramidal cells of 3xTg-AD mice exhibit a marked
transient increase in metabolic activity. Longer application reveals an accumulation of glucose smaller in pyramidal cells from 3xTg-AD than from non-Tg mice.
Layer II and III pyramidal cells were first visually identified
on the basis of the triangular shape of their soma and by
the presence of a prominent apical dendrite. Pyramidal
cells typically fired long duration action potentials with a
pronounced frequency adaptation (Figure 6A and Tables 2–5)
characteristic of Regular Spiking neurons (McCormick
et al., 1985; Cauli et al., 1997; Karagiannis et al., 2009;
Lacroix et al., 2015). We did not observe any difference
between the electrophysiological properties of non-Tg and
3xTg-AD juvenile pyramidal cells (Tables 2–5), consistent with
previous reports (Yamamoto et al., 2011 ). Their glutamatergic
phenotype was further confirmed by the detection of vGluT1
mRNAs and the absence of GAD65 and GAD67 transcripts
(Figures 6B,C).
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FIGURE 5 | Sensitivity of the RT-mPCR. Total whole brain RNAs (1 ng) were
subjected to a RT-PCR protocol. The PCR products were resolved in separate
lanes by agarose gel electrophoresis in parallel with 8×174 digested by HaeIII
as molecular marker and stained with ethidium bromide. The amplified
fragments correspond to neuronal markers (left), glucose transporters and key
enzymes of glucose metabolic pathways (right).
GluT1 and GluT3 mRNAs were respectively detected in 29%
(n = 9 of 31 cells) and 48% (n = 15 of 31 cells) in non-Tg neurons
and in 18% (n = 5 of 28 cells, p = 0.3703) and 21% (n = 6 of 28
cells, p = 0.0555) in 3xTg-AD neurons (Figures 6B,C). GluT1 and
GluT3 transcripts were rarely co-detected in both non-Tg (23%,
n = 7 of 31 cells) and 3xTg-AD neurons (4%, n = 1 of 28 cells,
p = 0.0547). Similar proportions of neurons were found to express
only GluT1 or only GluT3 in non-Tg and 3xTg-AD neurons (7%,
n = 2 of 31 cells vs. 14%, n = 4 of 28 cells, p = 0.4092 for GluT1
and 26%, n = 8 of 31 cells vs. 18%, n = 5 of 28 cells, p = 0.5398
for GluT3, respectively). Finally, we detected at least one of these
two GluTs in a similar proportion of non-Tg (55%, n = 17 of 31
cells) and 3xTg-AD neurons (36%, n = 10 of 28 cells, p = 0.1925).
These observations are consistent with the similar glucose uptake
capacity that we observed in non-Tg and 3xTg-AD layer II and
III pyramidal cells (Figure 2).
Similarly, the frequency of detection of HK1 was not different
between non-Tg (42%, n = 13 of 31 cells) and 3xTg neurons
TABLE 2 | Subthreshold properties of pyramidal cells.
Non-Tg (n = 31) 3xTg-AD (n = 28)
Resting potential (mV) −74.2 ± 1.6 −74.6 ± 1.4
U(31,28) = 403 p = 0.6458
n.s.
Input resistance (M) 541 ± 50 485 ± 42
U(31,28) = 388 p = 0.4926
n.s.
Time constant (ms) 46.1 ± 3.0 46.4 ± 2.8
U(31,28) = 415 p = 0.7805
n.s.
Membrane capacitance (pF) 96.2 ± 6.1 103.9 ± 6.3
U(31,28) = 364 p = 0.2938
n.s.
Sag Index (%) 10.8 ± 1.2 11.8 ± 1.4
U(31,28) = 389 p = 0.5022
n.s.
n, number of cells; n.s., not statistically significant.
Mann–Whitney U tests and corresponding exact p values.
(54%, n = 15 of 28 cells, p = 0.4390). Pfkfb3 was only detected
in a minority of pyramidal cells of non-Tg (13%, n = 4 of 31 cells)
and 3xTg-AD (4%, n = 1 of 28 cells, p = 0.3563, Figures 6B,C).
The most frequently detected phosphofructokinase-1 isoforms in
both non-Tg and 3xTg-AD neurons were PFK1m (84%, n = 26
of 31 cells and 64%, n = 18 of 28 cells, p = 0.1339, Figures 6B,C)
and PFK1p (58%, n = 18 of 31 cells, and 50%, n = 14 of 28 cells,
p = 0.3598, Figures 6B,C). PFK1l was observed in 36% (n = 11 of
31 cells) and 29% (n = 8 of 28 cells, p = 0.3874, Figures 6B,C) in
non-Tg and 3xTg-AD neurons, respectively.
G6PDx was detected in 16% (n = 5 of 31 cells) and 18%
(n = 5 of 28 cells) of the non-Tg and 3xTg-AD pyramidal cells,
respectively (p = 1.000, Figures 6B,C). The glycogen synthase
Gys1 was never detected in non-Tg neurons and rarely in 3xTg-
AD neurons (7%, n = 2 out of 28, p = 0.2209, Figures 6B,C).
Finally, the glycogen phosphorylase, PygB was observed in
TABLE 3 | Just above threshold properties of pyramidal cells.
Non-Tg (n = 31) 3xTg-AD (n = 28)
Rheobase (pA) 17.2 ± 4.4 18.1 ± 6.9
U(31,28) = 426 p = 0.9101
n.s.
First spike latency (ms) 274.0 ± 24.4 248.9 ± 23.2
U(31,28) = 376 p = 0.3855
n.s.
Adaptation (Hz/s) −1.7 ± 1.2 −0.6 ± 0.4
U(31,28) = 421 p = 0.8506
n.s.
Minimal steady state frequency (Hz) 5.2 ± 0.4 4.5 ± 0.3
U(31,28) = 389 p = 0.5022
n.s.
n, number of cells; n.s., not statistically significant.
Mann–Whitney U tests and corresponding exact p values.
TABLE 4 | Firing properties of pyramidal cells.
Non-Tg (n = 31) 3xTg-AD (n = 28)
Amplitude accommodation (mV) 5.6 ± 1.2 6.8 ± 1.0
U(31,28) = 321 p = 0.0878
n.s.
Amplitude of early adaptation (Hz) 42.1 ± 4.1 50.2 ± 4.2
U(31,28) = 334 p = 0.1317
n.s.
Time constant of early adaptation (ms) 24.2 ± 1.5 22.7 ± 1.5
U(31,28) = 372 p = 0.3532
n.s.
Maximal steady-state frequency (Hz) 29.3 ± 1.2 31.8 ± 1.6
U(31,28) = 333 p = 0.1278
n.s.
Late adaptation (Hz/s) −12.8 ± 0.8 −12.2 ± 0.7
U(31,28) = 412 p = 0.7460
n.s.
n, number of cells; n.s., not statistically significant.
Mann–Whitney U tests and corresponding exact p values.
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TABLE 5 | Action potential waveforms of pyramidal cells.
Non-Tg (n = 31) 3xTg-AD (n = 28)
1st spike amplitude (mV) 88.3 ± 1.7 88.7 ± 1.9
U(31,28) = 398 p = 0.5926
n.s.
2nd spike amplitude (mV) 85.8 ± 1.7 86.4 ± 2.0
U(31,28) = 391 p = 0.5216
n.s.
1st spike duration (ms) 1.7 ± 0.0 1.7 ± 0.1
U(31,28) = 413 p = 0.7574
n.s.
2nd spike duration (ms) 1.8 ± 0.0 1.8 ± 0.1
U(31,28) = 390 p = 0.5119
n.s.
Amplitude reduction (%) 2.9 ± 0.4 2.7 ± 0.4
U(31,28) = 405 p = 0.6676
n.s.
Duration increase (%) 6.5 ± 0.7 5.7 ± 0.9
U(31,28) = 353.5 p = 0.2236
n.s.
1st spike, 1st component
AHP (mV)
−9.8 ± 0.7 −9.8 ± 0.5
U(31,28) = 398.5 p = 0.5926
n.s.
1st spike, 1st AHP
component latency (ms)
8.4 ± 0.4 9.3 ± 0.7
U(31,28) = 431 p = 0.9700
n.s.
1st spike, 2nd component
AHP (mV)
−15.7 ± 0.6 −15.4 ± 0.4
U(31,28) = 361 p = 0.2733
n.s.
1st spike, 2nd AHP
component latency (ms)
47.3 ± 2.2 44.1 ± 2.3
U(31,28) = 364 p = 0.2938
n.s.
1st spike, ADP (mV) 0.0 ± 0.0 0.1 ± 0.0
U(31,28) = 430 p = 0.9580
n.s.
1st spike, ADP latency (ms) 0.5 ± 0.4 0.6 ± 0.4
U(31,28) = 431 p = 0.9700
n.s.
2nd spike, 1st component
AHP (mV)
−9.5 ± 0.8 −9.7 ± 0.5
U(31,28) = 406 p = 0.6786
n.s.
2nd spike, 1st AHP
component latency (ms)
8.9 ± 0.4 9.4 ± 0.6
U(31,28) = 368 p = 0.3226
n.s.
2nd spike, 2nd component
AHP (mV)
−15.9 ± 0.6 −16.1 ± 0.4
U(31,28) = 422 p = 0.8625
n.s.
2nd spike, 2nd AHP
component latency (ms)
47.5 ± 2.3 46.2 ± 2.1
(Continued)
TABLE 5 | Continued
Non-Tg (n = 31) 3xTg-AD (n = 28)
U(31,28) = 400 p = 0.6136
n.s.
2nd spike, ADP (mV) 0.0 ± 0.0 0.3 ± 0.3
U(31,28) = 418.5 p = 0.8154
n.s.
2nd spike, ADP latency
(ms)
0.0 ± 0.0 2.9 ± 0.4
U(31,28) = 418.5 p = 0.8154
n.s.
n, number of cells; n.s., not statistically significant.
Mann–Whitney U tests and corresponding exact p-values.
similar proportions in non-Tg (29%, n = 9 out of 31) and
3xTg-AD pyramidal cells (29%, n = 8 out of 28, p = 1.000,
Figures 6B,C).
DISCUSSION
Here we studied glucose metabolism of juvenile supragranular
pyramidal cells and its early alteration in a mouse model of AD.
Using intracellular glucose imaging and scRT-mPCR, we found
that glucose uptake was effective in juvenile pyramidal cells and
was not altered in 3xTg-AD mice. We also observed that both
glycolysis and pentose phosphate pathway were active under
resting condition. Interestingly, in 3xTg-AD neurons the pentose
phosphate pathway was reduced in favor of glycolysis (Figure 7).
IAA application also disclosed that another glucose metabolic
pathway might be active in 3xTg-AD neurons. The scRT-mPCR
analysis allowed to establish the three expression profile of
glucose metabolism key genes in pyramidal neurons, which
appeared qualitatively unaltered in 3xTg-AD mice. This indicates
that the metabolic alterations observed in 3x-Tg-AD pyramidal
neurons are possibly due to post-transcriptional modifications.
Intracellular Glucose Imaging in
Pyramidal Cells
We visualized the dynamics of intracellular glucose level using
a genetically encoded biosensor exhibiting changes in FRET
upon glucose binding but insensitive to phosphorylated glucose
or glycolytic intermediates (Fehr et al., 2003; Deuschle et al.,
2005; John et al., 2008; Takanaga et al., 2008; Bittner et al.,
2011; Hou et al., 2011; Barros et al., 2013). The glucose sensor
FLII12Pglu-700 µδ6 was transduced using a Sindbis vector which
exhibits a strong tropism toward pyramidal cells (Chen et al.,
2000; Lendvai et al., 2000; Furuta et al., 2001; Drobac et al.,
2010). Consistently, a large majority of transduced cells were
immunopositive for Satb2 (Figure 1), a transcription factor of
pyramidal cells (Britanova et al., 2008; Tasic et al., 2016). Given
that not all upper-layer pyramidal cells express Satb2 (Britanova
et al., 2008; Tasic et al., 2016), the proportion of excitatory
neurons expressing the glucose sensor is likely to be higher. Thus,
our glucose imaging experiments performed in layer II and III
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FIGURE 6 | Characterization of key molecular elements of glucose
metabolism in layer II and III pyramidal cells. (A) Voltage responses (upper
traces) induced by injection of current pulses (bottom traces) in a non-Tg layer
II and III pyramidal cell. In response to just-above-threshold current pulse, this
neuron fired an action potential with a long lasting biphasic AHP (middle
trace). Near saturation it showed the typical firing of a regular spiking neuron
with marked frequency adaptation and spike amplitude accommodation
(shaded trace). (B) The pyramidal cell shown in (A) expressed vGluT1, GluT1,
GluT3, HK1, pfkfb3, PFK1m, PFK1l, PFK1p, and G6PDx. (C) Histograms
showing the expression profiles of key molecular elements of glucose
metabolism in layer II and III pyramidal cells of non-Tg (black) and 3xTg-AD
mice (red). No statistically significant difference in the occurrence of genes
was observed. Note the very low occurrence of pfkfb3 and Gys1 (glycogen
synthase) in pyramidal neurons.
largely reflects the metabolic activity of upper layer pyramidal
cells.
Glucose Uptake
In addition to GluT3, a well established neuronal glucose
transporter (Nagamatsu et al., 1992; McCall et al., 1994; Fields
et al., 1999), we also detected GluT1 in a minority of pyramidal
cells. Although, GluT1 is more classically described in glial and
endothelial cells (Kacem et al., 1998; McEwen and Reagan, 2004;
Simpson et al., 2007; Winkler et al., 2015), recent transcriptomic
studies have revealed GluT1 expression in neurons (Cahoy
et al., 2008), including layer II and III cortical pyramidal cells
(Tasic et al., 2016). These observations indicate that juvenile
supragranular pyramidal cells express GluT3 and/or GluT1
transcripts.
Intracellular glucose imaging revealed that juvenile pyramidal
cells have the capacity to take up glucose (Figure 2). This is
consistent with the relatively low rate of glucose uptake reported
in resting cortical neurons (Chuquet et al., 2010; Diaz-Garcia
et al., 2017). Furthermore, we observed a low occurrence of
GluT1 and GluT3 mRNAs (Figure 6), in agreement with the
low expression level of these transporters in rodents during the
first postnatal weeks (Khan et al., 1999; Vannucci and Simpson,
2003). Since scRT-mPCR sensitivity is limited by the abundance
of transcripts and by the amount of cytoplasm collected (Cauli
and Lambolez, 2010; Devienne et al., 2018), this technique barely
detects transcripts expressed at a very low single cell level.
This could explain the relatively low level of GluT1 and GluT3
detection in pyramidal cells despite a glucose uptake capacity
that we observed in virtually all analyzed neurons. In addition,
since the proportion of neurons expressing at least one GluT
is higher than that of those expressing a given GluT, a lack of
GluT1 expression is likely to be functionally compensated by
expression of GluT3 and vice versa. Along this line, functional
compensation of glucose transport could be also achieved by
other glucose transporters such as GluT6 whose transcripts have
been consistently reported in cortical neurons (Cahoy et al., 2008;
Tasic et al., 2016). Altogether, our observations indicate that
at this juvenile stage, when energy metabolism is still heavily
dependent on ketone bodies (Nehlig, 1999), pyramidal cells can
already use glucose.
Neither GluT1 and 3 expression nor glucose uptake capacity
was altered in juvenile 3xTg-AD pyramidal cells. Indeed,
quantitative impairments in GluTs expression and glucose
utilization have only been reported after 6 months of age in 3xTg-
AD mice (Nicholson et al., 2010; Chen et al., 2012; Ding et al.,
2013).
Glucose Fate in Juvenile Pyramidal Cells
HK1, the predominant brain hexokinase isoform (Wilkin and
Wilson, 1977; Fields et al., 1999; Khan et al., 1999) was detected
in a substantial proportion of pyramidal neurons confirming its
expression at a relatively low level in this cell type (Tasic et al.,
2016). This suggests that juvenile pyramidal cells have already
the ability to metabolize glucose into glucose-6 phosphate as
indicated by our glucose imaging observations (Figures 3, 7).
As previously observed (Zeitschel et al., 1996; Bigl et al.,
2003; Cahoy et al., 2008; Tasic et al., 2016), the key enzymes
of glycolysis PFK1m and PFK1p, but also FPK1l to a lesser
extent, were frequently detected in juvenile pyramidal cells. In
contrast, pfkfb3 was rarely detected (Tasic et al., 2016). These
molecular data indicate that pyramidal cells are well equipped for
glycolysis. To evaluate functionally glycolysis fluxes in slices, we
applied 200 µM IAA for 30 min. Such a treatment achieves an
efficient glycolysis inhibition reducing NADH level within 5 min
(Gordon et al., 2008) in agreement with IAA-induced G3PDH
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FIGURE 7 | Resting glucose metabolism of juvenile pyramidal cells and its alterations in 3xTg-AD mice. Glucose uptake is facilitated via glucose transporters (GluT).
Once in the cytoplasm glucose phosphorylation by Hexokinase1 (HK1) yields to glucose 6-phosphate (G6P), the common substrate of different metabolic pathways.
Glucose-6-phosphate dehydrogenase (G6PDH) is the rate limiting enzyme of the pentose phosphate pathway leading to ribose-5-phosphate (R5P). Pentose
phosphate pathway is blocked by the G6PDH inhibitor, 6-aminonicotinamide (6-AN). G6P can also be isomerized into fructose-6-phosphate (F6P), a common
intermediate of the glycolysis and the hexosamine biosynthetic pathway. Glycolysis is blocked by Iodoacetic acid (IAA) inhibiting glyceraldehyde-3-phosphate
dehydrogenase (G3PDH). Glutamine:fructose-6-phosphate amidotransferase (GFAT), the rate limiting enzyme of the hexosamine biosynthetic pathway, converts
fructose-6-phosphate and glutamine into glucosamine-6-phosphate (GlcN6P) and glutamate (glutamine and glutamate are omitted for the sake of simplicity). G6P is
also the precursor of glycogen whose synthesis is normally absent in neurons (gray arrow). Dashed arrows indicate multisteps reactions. Functional changes in
3xTg-AD neurons are depicted by red arrows. Thicker and thinner arrows denote increased and decreased pathways, respectively.
inhibition, all the while minimizing unspecific effects (Dringen
et al., 1993). Blockade of the glycolytic flux generates a progressive
accumulation of glucose-6-phosphate (Bittner C.X. et al., 2010)
which in turn strongly inhibits HK1 (Liu et al., 1999), leading
to an intracellular glucose increase (John et al., 2008). During
IAA exposure, we consistently observed a delayed accumulation
of intracellular glucose. Confirming a recent report (Diaz-Garcia
et al., 2017), our results collectively reveal an active glycolysis in
juvenile pyramidal cells (Figures 4A, 7).
G6PDx is a major rate limiting enzyme of the pentose
phosphate pathway. In agreement with previous observations
(Ninfali et al., 1998; Cahoy et al., 2008; Tasic et al., 2016), we
detected its transcripts suggesting that juvenile pyramidal cells
can also use glucose for the pentose phosphate pathway. To
determine functionally the activity of this metabolic pathway we
used 6-AN, an inhibitor of two key enzymes, G6PDH and 6-
phosphogluconate dehydrogenase (Lange and Proft, 1970; Kohler
et al., 1970) which has a mild impact on glycolysis in the short
term (Hothersall et al., 1981; Haghighat and McCandless, 1997).
Blockade of the pentose phosphate pathway with 6-AN induced
an increase of intracellular glucose in non-Tg juvenile pyramidal
cells (Figures 4B, 7). Taken together, our data indicate that
pentose phosphate pathway is active in these neurons.
Under physiological conditions, glycogen is absent from
neurons (Vilchez et al., 2007). Consistent with previous reports
(Zeisel et al., 2015; Tasic et al., 2016), the glycogen synthase
(Gys1), and the glycogen phosphylase (PygB), were rarely
detected in non-Tg pyramidal cells.
Overall our molecular and imaging data indicate that the
glycolysis and the pentose phosphate pathway are the two main
active glucose pathways in juvenile pyramidal cells (Figure 7).
Alteration of Glucose Metabolic
Pathways in 3xTg-AD Pyramidal Cells
We observed a higher glycolytic activity and a less active pentose
phosphate pathway in 3xTg-AD juvenile pyramidal neurons
(Figure 7). Interestingly a NMR study has reported an increased
neuronal glycolysis in 7-months old 3xTg-AD mice (Sancheti
et al., 2014b) indicating that the higher glycolytic activity
develops early and persists before aging (Sancheti et al., 2014a).
Consistently, a recent metabolomic study revealed a higher
lactate plasma level in 8-months old 3xTg-AD mice (Sanguinetti
et al., 2018) that could result from a higher neuronal glycolytic
flux (Diaz-Garcia et al., 2017).
Our molecular observations did not reveal any significant
change in the expression profile of key molecular elements
of glucose metabolism in 3xTg-AD juvenile pyramidal cells.
However given the detection limits of the scRT-mPCR discussed
above and the relatively low occurrence G6PDx transcripts, it is
possible that the lower pentose phosphate pathway observed in
3xTg-AD mice derives from a reduction of G6PDx expression. To
our knowledge, changes in the expression profile of key molecular
elements of glucose metabolism in 3xTg-AD mice have only
been reported after 6 months of age (Chen et al., 2012; Ding
et al., 2013). This suggests that the early alterations of metabolic
activity are likely mediated by post-transcriptional and/or
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post-translational modifications. Interestingly, microRNA-34a
overexpression reduces G6PDH protein level and was found to be
increased in the temporal cortex of both 3xTg-AD mice and AD
patients (Sarkar et al., 2016). Similarly, the activity of several key
elements controlling glucose pathways are regulated at the post-
translational level (Khan et al., 1999; Almeida et al., 2004; Vilchez
et al., 2007; Bolanos et al., 2008; Herrero-Mendez et al., 2009).
Given the low level of detection of pfkfb3 (Figure 6; Tasic et al.,
2016), it is unlikely that 3xTg-AD pyramidal cells upregulate
glycolysis via fructose 2,6-bisphosphate production (Almeida
et al., 2004; Herrero-Mendez et al., 2009). Exposure to Aβ
peptides has been shown to increase the glycolytic activity of
astrocytes (Allaman et al., 2010). It would be interesting to
determine whether Aβ peptides, even at very low level, could
be responsible for the early alterations we observed in 3xTg-AD
pyramidal cells. Further investigations will be needed to elucidate
the underlying mechanisms.
Upon IAA application, we observed a transient increase in
glucose utilization in 3xTg-AD pyramidal cells. A rerouting
of glucose utilization toward the pentose phosphate pathway
and/or glycogenesis is unlikely given that the increased glucose
consumption induced by IAA persisted in presence of 6-AN
(Figure 4C) and that pyramidal neurons rarely express glycogen
synthase (Figure 6; Zeisel et al., 2015; Tasic et al., 2016). An
alternative possibility would be an increased glucose utilization
via the hexosamine biosynthetic pathway which competes
with glycolysis for fructose-6-phosphate (Figure 7). The entry
in this metabolic pathway is controlled by the rate limiting
enzyme glutamine:fructose-6-phosphate amidotransferase
(GFAT), which converts fructose-6-phosphate and glutamine
to glucosamine-6-phosphate and glutamate (Buse, 2006).
Interestingly, 3xTg-AD mice exhibit a temporary increased
brain level of glutamine (Sancheti et al., 2014a,b) that could
account for its higher plasma level (Sanguinetti et al., 2018).
Thus, upon glycolysis inhibition, the hexosamine biosynthetic
pathway could be favored by an enhanced availability of
the two GFAT substrates in these mice. Indeed, IAA will
induce a retrograde increase of the glycolysis intermediaries
before HK inhibition by glucose-6-phosphate (Liu et al., 1999)
and subsequent glucose accumulation (John et al., 2008).
Thus fructose-6-phosphate would be then transiently available
to feed the hexosamine biosynthetic pathway. Glutamine
synthesis largely relies on astrocytes metabolism. In slices,
IAA application would also affect astrocytes glycolysis and
would lead to a shortage in glutamine production. Therefore,
an enhanced flux of the hexosamine biosynthetic pathway in
3xTg-AD pyramidal cells is expected to be transient. This
hypothesis is compatible with the fast inhibition of G3PDH
by IAA in astrocytes (Gordon et al., 2008) and the kinetics
of the transient decrease in intracellular glucose observed
(Figure 4).
Interestingly, the hexosamine biosynthetic pathway is essential
for O-N-acetylglucosamine glycosylation, a process that protects
tau protein against hyperphosphorylation (Liu et al., 2009;
Gatta et al., 2016). An increased activity of this pathway might
represent an early adaptive mechanism to prevent and/or delay
neurofibrillary tangles formation in pyramidal cells. The later
impairment of glucose uptake (Nicholson et al., 2010; Ding et al.,
2013) and decreased levels of glutamine (Sancheti et al., 2014a)
observed in 3xTg-AD mice is likely to reduce the activity of the
hexosamine pathway leading to tau hyperphosphorylation and
tangles formation (Oddo et al., 2003; Carroll et al., 2010; Gatta
et al., 2016).
CONCLUSION
Despite a low cerebral glucose metabolism in suckling rodents
(Nehlig, 1999), its qualitative alterations in 3xTg-AD pyramidal
cells at a very early stage may have deleterious consequences for
their activity and survival in the long-term. Indeed, neurons are
poorly equipped to detoxify methylglyoxal, a harmful glycolysis
byproduct (Belanger et al., 2011). An increased glycolytic activity
is therefore expected to alter pyramidal cells survival (Herrero-
Mendez et al., 2009). Similarly, a decreased pentose phosphate
pathway would reduce the capacity of neurons to produce
glutathione, impairing their ability to detoxify reactive oxygen
species (Vaughn and Deshmukh, 2008). A higher glycolysis
activity combined with a reduced pentose phosphate pathway
would dramatically increase pyramidal cell vulnerability. This
could contribute to their degeneration which occurs before
amyloid deposition (Bittner T. et al., 2010). Further investigations
will be required to determine how these metabolic alterations
evolve during maturation and to identify their underlying
mechanisms, which could provide potential targets for drug-
modifying therapies.
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